Phosphatidylinositol-4,5-bisphosphate (PI(4,5)P 2 ), a minor component of the plasma membrane, is important in signal transduction, exocytosis, and ion channel activation. Thus fluorescent probes suitable for monitoring the PI(4,5)P 2 distribution in living cells are valuable tools for cell biologists. We report here three experiments that show neomycin labeled with either fluorescein or coumarin can be used to detect PI(4,5)P 2 in model phospholipid membranes. First, addition of physiological concentrations of PI(4,5)P 2 (2%) to lipid vesicles formed from mixtures of phosphatidylcholine (PC) and phosphatidylserine (PS) enhances the binding of labeled neomycin significantly (40-fold for 5:1 PC/PS vesicles). Second, physiological concentrations of inositol-1,4,5-trisphosphate (10 WM I(1,4,5)P 3 ) cause little translocation of neomycin from PC/PS/PI(4,5)P 2 membranes to the aqueous phase, whereas the same concentrations of I(1,4,5)P 3 cause significant translocation of the green fluorescent protein/phospholipase C-N pleckstrin homology (GFP-PH) constructs from membranes (Hirose et al., Science, 284 (1999) 1527. Third, fluorescence microscopy observations confirm that one can distinguish between PC/PS vesicles containing either 0 or 2% PI(4,5)P 2 by exposing a mixture of the vesicles to labeled neomycin. Thus fluorescently labeled neomycin could complement GFP-PH constructs to investigate the location of PI(4,5)P 2 in cell membranes. ß
Introduction
Although phosphatidylinositol-4,5-bisphosphate (PI(4,5)P 2 ) comprises only about 1% of the phospholipids in a mammalian cell plasma membrane [1, 2] , it plays at least ¢ve important roles in cellular processes. First, hydrolysis of PI(4,5)P 2 by phosphoinositide-speci¢c phospholipase C (PLC) [3] produces the second messengers inositol-1,4,5-trisphosphate (I(1,4,5)P 3 ) and diacylglycerol, which release calcium from intracellular stores and activate protein kinase C [4^6]. Furthermore, PI(4,5)P 2 binds to the pleckstrin homology (PH) domain of PLC-N with high (WM) a¤nity [7, 8] . Second, PI-3 kinase phosphorylates PI(4,5)P 2 to produce phosphatidylinositol-3,4,5-trisphosphate (PI(3,4,5)P 3 ), a lipid that has been implicated in regulating cell metabolism, proliferation, and survival [9] . Third, PI(4,5)P 2 may play a role in cytoskeleton rearrangements [10, 11] . Fourth, there is strong evidence that PI(4,5)P 2 is required for exocytosis [12^14] . Fifth, PI(4,5)P 2 regulates the activity of ion channels, e.g. K ATP channels [15^18] , and enzymes, e.g. phospholipase D (PLD) [19] .
How can PI(4,5)P 2 play so many di¡erent roles? One widely discussed possibility is that localization of PI(4,5)P 2 to di¡erent cellular membranes and lateral domains within a membrane allows segregation of the di¡erent signaling pathways that depend on PI(4,5)P 2 [14, 20] . Biochemical analysis, e.g. membrane fractionation and lipid extraction [2,21^24] , indicate PI(4,5)P 2 is localized mainly in the plasma membrane, nucleus, and synaptic vesicles [12, 25, 26] . It is important to have probes speci¢c for PI(4,5)P 2 that can be observed in living cells using a non-invasive method, such as £uorescence microscopy.
Constructs of the PLC-N PH domain with green £uorescent protein (GFP) have been used to study PI(4,5)P 2 distribution in living cells [27, 28] . Previous studies showed this PH domain binds speci¢cally, with WM a¤nity to PI(4,5)P 2 [7, 8] . The molecular basis for the speci¢city is understood. The PLC-N PH domain is a rigid cage-like structure that does not undergo a signi¢cant change in conformation when it binds to the headgroup of PI(4,5)P 2 [29] . Fluorescence microscopy studies of the GFP-PH constructs show that a major pool of PI(4,5)P 2 in quiescent cells is in the plasma membrane [27, 28] , in agreement with the results from biochemical analyses and immuno£uorescence studies with PI(4,5)P 2 -speci¢c antibodies [30, 31] . Activation of PLC (e.g. by increasing the Ca 2 concentration in the cytoplasm [28] or stimulating the receptor for platelet activating factor [27] ) produces rapid redistribution of the GFP-PH constructs to the cytosol. This redistribution of GFP-PH construct is interpreted as re£ecting a decrease in the PI(4,5)P 2 concentration in the plasma membrane. A recent study [32] suggests, however, that translocation of the GFP-PH constructs to the cytosol might re£ect an increase in cytosolic I(1,4,5)P 3 rather than a decrease in PI(4,5)P 2 in the plasma membrane. Previous studies [7, 8] demonstrated that the PLC-N PH domain binds 10-fold more strongly to I(1,4,5)P 3 than to PI(4,5)P 2 , so a small increase in cytosolic I(1,4,5)P 3 could cause a signi¢cant redistribution of the GFP-PH probe. Hence, new probes that are speci¢c for PI(4,5)P 2 but do not have a higher a¤nity for I(1,4,5)P 3 are needed to complement the GFP-PLC-N PH constructs in studies of the inositol phospholipid role in cellular functions.
Here we explore whether £uorescently labeled neomycins may be used as probes for PI(4,5)P 2 in biological membranes. We have chosen neomycin because it is a small molecule that binds strongly to PI(4,5)P 2 [33^35]. Neomycin is an aminoglycoside antibiotic with six primary amine groups and an average charge of +4.5 in a solution containing 100 mM KCl, pH 7 [36] 1 . Fig. 1 shows the chemical structures of £uorescently labeled neomycins used in this study. The a¤nity of neomycin for PI(4,5)P 2 in a PC/PI(4,5)P 2 membrane is about 10 5 M 31 [35] . We made three types of measurements. First, we determined if addition of a £uorophore to neomycin alters its interaction with PI(4,5)P 2 . Second, we tested whether addition of I(1,4,5)P 3 to the mixture of £uo-rescently labeled neomycin and vesicles displaces the probe from the membrane. Third, we tested if the labeled neomycin can be used to distinguish between phospholipid membranes with or without 1 In our hands small basic peptides that have been claimed to bind speci¢cally to PI(4,5)P 2 (for a review see [14] ), such as a peptide from PLC-N PH domain, show little a¤nity for PI(4,5)P 2 in direct equilibrium binding measurements [54] . Neomycin is the only small organic molecule that, to our knowledge, binds with WM a¤nity to PI(4,5)P 2 .
physiological concentrations of PI(4,5)P 2 , 1^5% total lipid. We conclude that £uorescently labeled neomycin is a potentially useful probe that could complement GFP-PH constructs in the study of PI(4,5)P 2 distribution in cellular membranes.
Materials and methods

Materials
1-Palmitoyl-2-oleoyl-sn-glycero-3-phosphatidylcholine (PC), 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphatidylserine (PS), 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphatidylglycerol (PG), and lissamine rhodamine B-dipalmitoyl-phosphatidylethanolamine (Rh-PE) were purchased from Avanti Polar Lipids (Alabaster, AL). Radiolabeled 1,2-di[1-
14 C]oleoyl-L-3-phosphatidylcholine ([ 14 C]PC) was purchased from Amersham (Arlington Heights, IL), £uorescein-5-isothiocyanate (FITC), 7-amino-3-((((succinimidyl)oxy)-carbonyl)methyl)-4-methylcoumarin-6-sulfonic acid (AMCA-S), 6-((7-amino-4-methylcoumarin-3-acetyl)-amino)hexanoic acid, succinimidyl ester (AMCA-X), and 2-(3-(diphenylhexatrienyl) propanoyl)-1-hexadecanoyl-sn-glycero-3-phosphocholine (DPH-PC) were from Molecular Probes (Eugene, OR). PI(4,5)P 2 (ammonium salt) was isolated from bovine brain extract (Sigma, St. Louis, MO) as described previously [37] . Phosphatidylinositol-3,4-bisphosphate, dipalmitoyl, PI(3,4)P 2 (ammonium salt) was purchased from Matreya (Pleasant Gap, PA). Neomycin trisulfate was from Sigma. I(1,4,5)P 3 was from Calbiochem-Novabiochem (San Diego, CA) and Sigma. Our standard bu¡er solution consists of 100 mM KCl, 1 mM MOPS, pH 7.
Fluorescently labeled neomycin
Neomycin was labeled with FITC, AMCA-S, or AMCA-X as described below. For the labeling with FITC, neomycin trisulfate (45.4 mg, 0.05 mmol) and £uorescein isothiocyanate (FITC; 3.75 mg, 0.0083 mmol) were dissolved in 1 ml of 1 N TEAB (triethylammonium bicarbonate, pH 7.5); the solution was stirred for 1 h and left unstirred for 36 h at room temperature. The solution was concentrated in vacuum, and the residue was dissolved in 1 ml of water. Fig. 1 . Chemical structures of the £uorescent neomycin compounds used in this study. FITC is £uorescein-5-isothiocyanate, AMCA-S is 7-amino-3-((((succinimidyl)oxy)carbonyl)methyl)-4-methylcoumarin-6-sulfonic acid, and AMCA-X is 6-((7-amino-4-methylcoumarin-3-acetyl)amino)hexanoic acid. For each of these compounds, the neomycin can be modi¢ed at either of the two aminomethylene (^CH 2 NH 2 ) groups, and the material used is an inseparable mixture of the two isomers.
Aliquots of the solution (50 Wl each) were puri¢ed by HPLC on a C 18 silica gel reversed-phase column (0.45U25 cm), with a linear gradient elution of bu¡-er A (0.06% aq. tri£uoroacetic acid) to bu¡er B (95% acetonitrile, 5% water, 0.052% tri£uoroacetic acid), a £ow rate of 1 ml/min, and absorbance monitoring at 494 nm. A single fraction midway through the gradient was collected from each run, and those fractions were combined, concentrated, and lyophilized to give a yellow powder (5.5 mg, yield 64%). Electron spray mass spectrometry (ES-MS) gives m/z 1003.63 for the product. Calculated molecular weight is 1004.2. For labeling with AMCA-S, a coumarin derivative, neomycin trisulfate (27 mg, 0.0297 mmol) and AMCA-S-SE (7-amino-3-(((succinimidyl)oxycarbonyl)methyl)-4-methyl-coumarin-6-sulfonic acid, 2.0 mg, 0.050 mmol) were dissolved in 0.2 ml of 0.1 M NaHCO 3 (pH 7.55) and the solution was stirred for 24 h at room temperature. The solution was concentrated in vacuum, the residue was dissolved in 1 ml of water, and aliquots were puri¢ed by the same HPLC system as above except that detection was at 353 nm. Fractions containing the product were pooled together and lyophilized as described above to give a pale yellow powder (2.5 mg, yield 55%). ES-MS gives m/z 910.02. Calculated molecular weight is 910.58. For labeling with AMCA-X, another coumarin derivative, neomycin trisulfate (51.1 mg, 0.056 mmol) and AMCA-X-SE 6-(7-amino-4-methylcoumarin-3-acetyl)amino)hexanoic acid, succinimidyl ester (2.5 mg, 0.0056 mmol) were dissolved in 0.2 ml of 1 N TEAB and 0.1 ml of dimethylformamide (DMF). The solution was stirred for 5 h and left unstirred for 72 h at room temperature. The solution was processed as described for AMCA-S-neomycin to give a yellow powder (2.8 mg, yield 51%). ES-MS gives m/z 943.00. Calculated molecular weight is 944.04. The chemical structures of the compounds we used are shown in Fig. 1 . Fluorescently labeled neomycin was dissolved in water (Millipore ¢ltered and double quartz distilled) and stored frozen in small aliquots. We determined the concentration of the probe by measuring the absorbance of the £uorophores (for £uorescein O = 73 000 M 31 cm 31 , pH 9; for coumarin O = 19 000 M 31 cm 31 , methanol). The £uorescence intensity of FITC-and coumarinlabeled neomycin, either in solution or bound to a membrane, increases linearly over the range of concentrations we investigated (10^250 nM neomycin). Control experiments show £uorescently labeled neomycin (30^200 nM) remains in solution when the samples are centrifuged for 1 h. at 100 000Ug. This result is consistent with our assumption that the labeled neomycin exists as a monomer in solution. There is, however, some loss of the probe on the walls of the centrifuge tube; we minimized the loss by pre-washing the tubes with unlabeled neomycin sulfate. For FITC-neomycin it was su¤cient to prewash tubes with a solution containing the same concentration of neomycin that was used in the binding experiment. When the tubes were pre-washed, the concentration of labeled neomycin in bu¡er solution was the same before and after centrifugation, indicating this treatment prevents signi¢cant adsorption of the labeled aminoglycoside to the tube. Coumarinlabeled aminoglycosides adhere more strongly to the centrifuge tubes; hence we pre-washed the tubes with a solution containing a 10-fold higher concentration of unlabeled neomycin for experiments with this probes.
Vesicle preparation
We measured initial concentration of lipids in chloroform using a Cahn electrobalance. In some experiments, trace amounts of [ 14 C]PC were added to the lipid mixture to determine the ¢nal lipid concentration. The concentrations of I(1,4,5)P 3 and lipid in the solution were also con¢rmed by phosphate analysis [38] . Lipid mixtures were dried on a rotary evaporator and resuspended in a sucrose bu¡er (176 mM sucrose, 1 mM MOPS, pH 7) to produce multilamellar vesicles. Large unilamellar vesicles (LUVs) were made by extruding multilamellar vesicles 10 times through a stack of two polycarbonate ¢lters (100 nm pore diameter) after 5 freeze^thaw cycles [39] . Vesicles with and without PI(4,5)P 2 were prepared on the same day from the same stock of lipid solutions in chloroform. PI(4,5)P 2 in a membrane has an e¡ective net charge of 33 in a 100 mM KCl, pH 7 solution [36] . Thus we replaced 3 PS by 1 PI(4,5)P 2 in the PC/PS/PI(4,5)P 2 vesicles to keep the charge density the same as in the PC/PS vesicles.
All preparations, binding measurements, and microscopy observations were made at room temperature, 22^23³C.
Equilibrium binding measurements
Equilibrium binding of labeled neomycins was determined using a sucrose-loaded vesicles assay [40] . Brie£y, labeled neomycin was mixed with the sucrose-loaded vesicles in 100 mM KCl and the mixture was centrifuged (1 h, 100 000Ug) to separate the vesicles, which form a pellet, from the unbound neomycin. The supernatant was removed carefully and its FITC £uorescence was measured (the structure of the labeled neomycin is shown in Fig. 1 ). In the experiments with FITC-neomycin, the FITC £uores-cence of the supernatant re£ects how much neomycin remained unbound. We obtained the same binding a¤nity (see Eqs. 1 and 3) using two di¡erent FITC-neomycin concentrations (100 and 200 nM), which controls for a number of possible artifacts (e.g. that FITC-neomycin does not change the vesicle surface charge density and that it binds as a monomer). We did not use pellet samples to calculate the binding because FITC-neomycin bound to a membrane gives a 5-fold lower signal than in solution. This is obviously a disadvantage of using this particular probe with biological membranes.
Coumarin £uorescence was the same from a labeled neomycin either in bu¡er or bound to a membrane for both AMCA-S-and AMCA-X-neomycin (the structures of the labels are shown in Fig. 1 ). Hence £uorescence measurements of both supernatant and pellet were used to calculate percent coumarin-neomycin bound as discussed in [40] . We obtained the same binding a¤nity (see Eqs. 1 and 3) using 35, 70, or 140 nM of AMCA-X-neomycin.
We describe neomycin binding to membranes with PI(4,5)P 2 in two ways. First, we determine a molar partition coe¤cient, K; this calculation does not require any assumptions about the mechanism(s) involved in the association of the probe with the membrane. Second, we assume that labeled neomycin forms a 1:1 complex with PI(4,5)P 2 and calculate the apparent speci¢c association constant, K NÀP , for this complex; this assumption is consistent with the available data for unlabeled neomycin [35, 36, 41] .
The molar partition coe¤cient, K, is the ratio of 
The accessible lipid concentration, the concentration of the lipid comprising the outer lea£et of the vesicles, equals about one half of the total lipid concentration for LUVs. In the limit of low neomycin concentration (when binding of neomycin does not change the a¤nity of the vesicle for the probe), K equals the reciprocal of the accessible lipid concentration that binds 50% of neomycin (i. 
Measurements of the e¡ect of I(1,4,5)P 3 addition on FITC-neomycin binding
We pre-mixed 80, 100, or 160 nM FITC-neomycin with sucrose-loaded 5:1 PC/PS vesicles with 1^2% PI(4,5)P 2 (several di¡erent lipid concentrations were used) and allowed the solution to equilibrate for 15 min. We then added di¡erent amounts of I(1,4,5)P 3 to the neomycin-vesicle solution. The samples were centrifuged (1 h, 100 000Ug), the superna-tant was removed, and FITC £uorescence was measured. Percent FITC-neomycin bound was calculated as described for standard equilibrium binding experiments.
The association constant of neomycin with I(1,4,5)P 3 is
where 
Preparation of giant vesicles for microscopy
Giant unilamellar vesicles for microscopy studies were prepared using a gentle hydration method [45] . For each experiment, we prepared two sets of vesicles with the same surface charge density: one set contained PI(4,5)P 2 ; the other set contained a £uores-cent marker, but no PI(4,5)P 2 . For example, we prepared 66:28:2 PC/PS/PI(4,5)P 2 and 2:1 PC/PS vesicles, where the latter contained 0.3 mol% DPH-PC, allowing us to distinguish these vesicles from the unlabeled vesicles containing PI(4,5)P 2 in a mixed sample. An appropriate lipid mixture in chloroform was dried in a v-shaped £ask on a rotary evaporator under vacuum for 30 min to form a thin ¢lm. The dried ¢lm was prehydrated for 20 min at 45³C with water-saturated argon, and 4^6 ml of the bu¡er solution was gently added to the £ask. The sealed £ask was incubated at 37³C for 12^24 h, and 100^200 Wl of the upper part of the solution was harvested and used for microscopy studies. Vesicles with or without PI(4,5)P 2 were mixed together at approximately the same concentrations and the ratio was checked by viewing a slide. After adding labeled neomycin to the vesicle mixture, we transferred the sample to a glass slide and added agarose to inhibit vesicle movement. A typical sample contained about 1 mM of lipid, 0.2^1 WM of neomycin and 0.5% w/v agarose. (We cannot measure the exact concentration of lipid on a slide because the solution of giant vesicles is very heterogeneous.)
We conducted the same experiments using also 5:1 PC/PS giant vesicles with and without 2 mol% PI(4,5)P 2 . We labeled the vesicles without PI(4,5)P 2 with either DPH-PC or Rh-DPPE. We obtained the same results using two di¡erent lipid markers. We also tested AMCA-X-neomycin.
Imaging
Images were obtained using a ¢xed stage microscope (Axioskop, Zeiss), Plan-NEOFLUOR 63U-oil objective (Zeiss), and Micro-Max Princeton CCD camera (Princeton). The £uorescence of FITC was measured using a short band path ¢lter set 41001 from Chroma: exciter 460 þ 20 nm, beam splitter 505 nm, and emitter 535 þ 25 nm. The £uorescence of coumarin or DPH was measured using a short band path ¢lter set 31000 from Chroma: exciter 360 þ 20 nm, beam splitter 400 nm, and emitter 460 þ 25 nm. Filters for rhodamine were from Omega Optical: exciter 510 þ 13.5 nm, emitter s 560 nm.
Results
We studied the binding of neomycin to phospholipid vesicles with and without PI(4,5)P 2 . Because neomycin has an average charge of +4.5 in 100 mM KCl, pH 7 [36] , it can bind to negatively charged membranes both via a non-speci¢c electrostatic accumulation in the di¡use double layer (Gibbs surface excess, for a review see [46] ) and by formation of a speci¢c complex with the acidic lipid PI(4,5)P 2 . To distinguish between these two possibilities, we measured the binding of £uorescently labeled neomycin to vesicles with the same surface charge density, but di¡erent concentrations of PI(4,5)P 2 .
The cytoplasmic lea£et of the plasma membrane of a typical mammalian cell contains 15^30 mol% PS and 1^2 mol% PI(4,5)P 2 [1, 21, 22, 25, 47 ]. Hence we ¢rst tested FITC-neomycin binding to phospholipid vesicles with 17 mol% (5:1 PC/PS) and 33 mol% (2:1 PC/PS) PS. Then we substituted 6 mol% PS in the lipid mixture with 2 mol% PI(4,5)P 2 to keep the surface charge density constant and measured the binding of labeled neomycin to these PI(4,5)P 2 containing vesicles. The results shown in Fig. 2A ,B indicate that FITC-neomycin binds speci¢cally to PI(4,5)P 2 . If Fig. 3 were done using sucrose-loaded vesicles and our standard bu¡er, 100 mM KCl, 1 mM MOPS, pH 7. 2 Binding of FITC-neomycin to PC/PS vesicles depends steeply on the mole fraction of PS in the membrane, as expected for this poly-basic compound. Binding of FITC-neomycin increases 25-fold when the mol% PS is increased 2-fold from 17 to 33 mol% (Fig. 2) .
PI(4,5)P 2 increases the binding of FITC-neomycin to phospholipid vesicles
we calculate the apparent speci¢c association constant, K NÀP , for a 1:1 neomycin:PI(4,5)P 2 complex from Eq. 3, we obtain K NÀP = 2U10 5 M 31 and 5U10 5 M 31 for vesicles with a surface charge density equivalent to 17 and 33 mol% PS, respectively. We also measured FITC-neomycin binding to 98:2 PC/ PI(4,5)P 2 vesicles and obtained a molar partition coe¤cient K = 1.5U10 3 M 31 and an apparent speci¢c association constant K NÀP = 10 5 M 31 (data not shown). The value of K NÀP is the same as that reported for unlabeled neomycin binding to PC/ PI(4,5)P 2 vesicles [35] ; thus, attachment of this £uo-rophore to neomycin does not a¡ect signi¢cantly neomycin a¤nity for PI(4,5)P 2 .
As an aside, we note that K NÀP is only an apparent binding constant because it depends on the surface charge density of the vesicles (mol% acidic lipid): for FITC-neomycin K NÀP equals 10 5 M 31 for PC/ PI(4,5)P 2 , 2U10 5 M 31 for 5:1 PC/PS+2 mol% PI(4,5)P 2 , and 5U10 5 M 31 for 2:1 PC/PS+2 mol% PI(4,5)P 2 vesicles. The K NÀP depends on the surface charge density of the vesicles (surface potential) because the concentration of poly-basic neomycin close to the negatively charged membrane is enhanced by a non-speci¢c long-range electrostatic attraction (Boltzmann factor) (see [35, 48] for a detailed discussion).
The molar partition coe¤cient increases linearly with mol % PI(4,5)P 2 in the membrane
To study how the binding of neomycin depends on the mol% PI(4,5)P 2 in a membrane, we measured binding of the FITC-labeled neomycin to 2:1 PC/ PS vesicles containing 0, 1, 2, or 4 mol% PI(4,5)P 2 . The results are summarized in Table 1 . The ¢rst column gives the composition of the vesicles used. The second column gives the values of K obtained by ¢tting Eq. 2 to the data from equilibrium binding experiments (data from Fig. 2B for 0 and 2 mol% PI(4,5)P 2 , data not shown for 1 and 4 mol% PI(4,5)P 2 ). There is a linear relation between the amount of PI(4,5)P 2 in the vesicles and the molar partition coe¤cient: increasing the mol% PI(4,5)P 2 in membrane 2-fold increases K approximately 2-fold. The third column gives the apparent speci¢c association constant, K NÀP , for neomycin and PI(4,5)P 2 calculated from the data using Eq. 3; as expected for a 1:1 complex, K NÀP is independent of the mol% PI(4,5)P 2 in the membrane.
All our equilibrium binding results are consistent with the formation of a 1:1 complex between PI(4,5)P 2 and FITC-neomycin, as was suggested by previous studies using unlabeled neomycin [35, 36, 41] .
PI(4,5)P 2 increases the binding of coumarin-labeled neomycin to 2:1 PC/PS vesicles
We also tested neomycin labeled with the coumarin derivatives AMCA-S and AMCA-X and obtained qualitatively similar results to those reported above for FITC-neomycin. Fig. 3 shows AMCA-X binding isotherms for 2:1 PC/PS vesicles and PC/PS/ PI(4,5)P 2 vesicles with the same surface charge density, with K = 2U10 4 M 31 and 1U10 5 M 31 , respectively. Addition of 2 mol% PI(4,5)P 2 increases binding of AMCA-X-labeled neomycin to 2:1 PC/PS vesicles 5-fold.
AMCA-S-neomycin binds to membranes 5-fold less strongly (data not shown) and AMCA-X-neomycin almost 10-fold more strongly than FITC-neomycin (compare Figs. 2B and 3 ). This increase in the Table 1 The molar partition coe¤cients and the apparent association constants for the FITC-neomycin binding to 2:1 PC/PS vesicles with 0^4 mol% PI(4,5) binding of AMCA-X-neomycin to membranes compared to binding of unlabeled neomycin could be due to a hydrophobic interaction of the £uorophore with the lipid head group region. The AMCA-X £uoro-phore has a hydrophobic linker (see Fig. 1 ) that could allow both electrostatic interaction of neomycin and hydrophobic interaction of coumarin with the membrane, increasing the binding.
FITC-neomycin does not distinguish between PI(3,4)P 2 and PI(4,5)P 2
We measured the binding of FITC-neomycin to 2:1 PC/PS vesicles containing 1 mol% phosphatidylinositol-3,4-bisphosphate (PI(3,4)P 2 ) or phosphatidylinositol-4,5-bisphosphate (PI(4,5)P 2 ) (data not shown). The FITC-neomycin binds equally well to vesicles with either 1 mol% PI(3,4)P 2 or with 1 mol% PI(4,5)P 2 . PI(4,5)P 2 is the major bisphosphate inositol lipid in mammalian cells and the distribution of the probe should reveal mainly its location in a living cell. Upon activation of PLC in a cell, it cleaves PI(4,5)P 2 to produce I(1,4,5)P 3 that might compete for a PI(4,5)P 2 -speci¢c probe. Because I(1,4,5)P 3 is cytosolic, binding of I(1,4,5)P 3 to the probe can cause translocation of the probe into the cytosol even when the level of PI(4,5)P 2 in the membrane does not change signi¢cantly: this probably occurs with the GFP-PLC-N PH constructs [32] . We tested whether addition of I(1,4,5)P 3 to the mixture of FITC-neomycin with 5:1 PC/PS vesicles containing 1^2 mol% PI(4,5)P 2 causes translocation of FITCneomycin from the membrane into the aqueous solution. In our experiments, the concentration of accessible PI(4,5)P 2 (2^10 WM) is approximately equal to the concentration of PI(4,5)P 2 present in a cell plasma membrane. Eq. 5 describes how the fraction of neomycin bound to PI(4,5)P 2 depends on the concentration of I(1,4,5)P 3 added to the aqueous phase. We can describe our experimental data on depen- dence of [N-PI(4,5)P 2 ] on the amount of I(1,4,5)P 3 added to the aqueous phase with a value for K NÀIP3 similar to the association constant of neomycin to PI(4,5)P 2 . Fig. 4 shows a typical result. In the absence of I(1,4,5)P 3 , 55% FITC-neomycin bound to 5:1 PC/PS vesicles with 2 mol% PI(4,5)P 2 (left hand data in Fig. 4) . Addition of 5, 10, or 20 WM I(1,4,5)P 3 changed the percent FITC-neomycin bound to the vesicles only slightly. The theoretical curve obtained from Eq. 5 with K NÀIP3 = 4U10 4 M 31 describes the experimental data adequately. This value for K NÀIP3 is comparable to, but slightly less than, the association constant for neomycin and PI(4,5)P 2 in a PC/PI(4,5)P 2 membrane, K NÀP = 1U10 5 M 31 . For 2:1 PC/PS membranes with 2 mol% PI(4,5)P 2 , or membranes with more PI(4,5)P 2 , we observed even less translocation of FITC-neomycin than is shown in Fig. 4 (data not shown), as expected from Eq. 5 for conditions where K NÀP is higher. From these data we conclude that 1^10 WM I(1,4,5)P 3 should not cause signi¢cant translocation of labeled neomycin from the plasma membrane into the cytoplasm.
Speci¢c binding of FITC-neomycin to giant
vesicles containing PI(4,5)P 2 can be detected using £uorescence microscopy
We studied the distribution of £uorescently labeled neomycin on vesicles with and without PI(4,5)P 2 in a mixture of the two types of vesicles using £uores-cence digital microscopy. Three kinds of images were taken from the same location on the slide. Phase contrast images revealed all the vesicles in focus at this location. DPH £uorescence images re- vealed vesicles prepared without PI(4,5)P 2 . FITC £uorescence images revealed vesicles that bound FITC-neomycin. A typical example of the images obtained is shown in Fig. 5A^C . The phase contrast image in Fig. 5A shows two large vesicles: a V20-Wm vesicle in the center that is slightly out of focus and a V10 Wm vesicle in the lower right corner. (A dot adjacent to the upper right corner of the large vesicle is an artifact.) Fig. 5B shows the image obtained through the ¢lter set for DPH dye: the central vesicle has DPH £uorescence and is from the preparation containing no PI(4,5)P 2 ; the lower vesicle has no DPH £uorescence, and thus contains PI(4,5)P 2 . Fig. 5C shows the image obtained through the ¢lter set for FITC dye: the lower vesicle reveals strong FITC £uorescence. This vesicle contains PI(4,5)P 2 and has FITC-neomycin bound to it, whereas there is almost no binding of FITC-neomycin to the upper vesicle that contains no PI(4,5)P 2 . The results shown here are consistent with the direct binding measurements presented in Fig. 2B .
We also detected FITC-neomycin bound only to 5:1 PC/PS with 2 mol% PI(4,5)P 2 vesicles in a mixture with 5:1 PC/PS vesicles with and without PI(4,5)P 2 . Preferential binding of AMCA-X-neomycin to giant unilamellar vesicles containing PI(4,5)P 2 was observed in £uorescence microscopy experiments similar to those shown in Fig. 5 using Rh-PE as a lipid marker for vesicles without PI(4,5)P 2 (data not shown). The results on PI(4,5)P 2 distribution obtained with coumarin-labeled neomycin are consistent with the results from the direct binding measurements shown in Fig. 3 . We conclude that £uorescently labeled neomycin can be used to distinguish between membranes with and without PI(4,5)P 2 using £uorescence microscopy.
Discussion
We report three major results. First, incorporating physiological concentrations of PI(4,5)P 2 (e.g. 2%) into a lipid bilayer increases the binding of £uores-cently labeled neomycin (Figs. 2 and 3 ). FITC-labeled neomycin binds to PI(4,5)P 2 -containing membranes to about the same degree as the unlabeled neomycin [33, 35] , and our results are consistent with formation of a 1:1 neomycin:PI(4,5)P 2 complex with an apparent association constant of 10 5 -10 6 M 31 (Table 1) . Second, I(1,4,5)P 3 causes little translocation of FITC-neomycin from membrane to the aqueous phase under conditions designed to correspond to those in a living cell (Fig. 4) . Third, we can detect the preferential binding of FITC or coumarin-labeled neomycin to vesicles containing 2% PI(4,5)P 2 in a mixture of vesicles with and without PI(4,5)P 2 using £uorescence microscopy on giant phospholipid vesicles (Fig. 5) . These three results suggest that £uorescently labeled neomycin could be useful as a probe for monitoring PI(4,5)P 2 distribution within cells, complementing the use of GFP-PH constructs recently developed by several groups [27,28] 3 There are two advantages of using neomycin. First, it is a small molecule and may probe PI(4,5)P 2 on the cell membranes where larger molecules like the GFP-PH constructs could be sterically inhibited from binding to PI(4,5)P 2 . Second, physiological concentrations of I(1,4,5)P 3 do not displace neomycin from the membrane (Fig. 4) . In contrast, I(1,4,5)P 3 binds avidly to the PLC-N PH domain and could produce translocation of the GFP-PH constructs from the membrane to the cytosol upon PLC activation; this could lead to erroneous conclusions regarding the PI(4,5)P 2 concentration in a membrane [32] . Thus £uorescently labeled neomycin, which is not displaced by I(1,4,5)P 3 from PI(4,5)P 2 -containing membranes, could be used together with the GFP-PH constructs. A few technical considerations about £uorescently labeled neomycin that might be useful to cell biologists are discussed in Appendix A.
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Appendix A
We expect that injection of 6 1 WM neomycin (a su¤cient neomycin concentration to detect PI(4,5)P 2 using a £uorescence microscope) will not interfere signi¢cantly with the inositol pathways in a cell. At this concentration, neomycin should bind less than 5% of the PI(4,5)P 2 . No cytotoxicity of neomycin was observed in human endothelial cells if added to the cells at low concentrations [49] . However, higher concentrations of neomycin are used routinely to inhibit PLC (for example, in [28, 50] ) and 100 WM to 5 mM of neomycin added to permeabilized cells perturbs turnover of the inositol phospholipids [33, 51, 52] . Therefore one should use low ( 6 1 WM) concentrations of the labeled neomycin.
The available evidence suggests that cell membranes are not permeable to neomycin. Fluorescently labeled neomycin could be either injected into cells or added to permeabilized cells. It can also be incorporated into cells using electroporation, a technique used routinely to transfect cells with DNA or RNA. We used the electroporation technique to introduce FITC-neomycin into mammalian kidney cells. Cells treated with electroporation with 0.5, 1, or 2 WM of FITC-neomycin in the media were highly £uorescent and had some staining inside the cell. Di¡use £uorescence from the cytoplasm possibly indicates that neomycin binds to other negatively charged molecules in a cell: e.g. it is known that neomycin binds to 16S ribosomal RNA in prokaryotic cells [53] and could bind to some RNA in eukaryotic cells. Thus FITC-neomycin may be less useful for studies in living cells than other £uorescently labeled neomycins because its £uorescence decreases when it binds to membranes. Neomycin labeled with rhodamine B, X-rhodamine isothiocyanate, or other labels has been used to investigate the uptake of neomycin and PI(4,5)P 2 into cells (S. Ozaki, D.B. DeWald, J.C. Shope, J. Chen and G.D. Prestwich, personal communication). Labeling of neomycin with a polarity sensitive £uorophore that gives a higher £uorescence signal when the probe is bound to a membrane (e.g. acrylodan) might be advantageous.
Fluorescently labeled neomycin derivatives may be obtained from one of the authors (G.D.P.) for collaborative projects. FITC, Texas Red, BODIPY, tetramethylrhodamine, rhodamine B, rhodamine-X, and other adducts have been prepared. Many of these are commercially available from Echelon Research Laboratories, (http://www.echelon-inc.com).
